Ac-SDKP vs BPC-157
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Ac-SDKP or BPC-157?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Ac-SDKP and BPC-157?
Ac-SDKP is an endogenous anti-fibrotic peptide released by thymosin beta-4 processing, with a known role in ACE inhibitor pharmacology; BPC-157 is a synthetic gastric peptide with broader but less independently validated preclinical claims.
Evidence Comparison
Ac-SDKP: endogenous tetrapeptide, levels naturally regulated by ACE; anti-fibrotic effects demonstrated by multiple independent research groups in cardiac, renal, and pulmonary fibrosis models. BPC-157: 70+ studies but almost entirely from the Sikiric group in Zagreb with no independent replication. Ac-SDKP has stronger mechanistic validation through independent work.
Evidence Context Favoring Ac-SDKP
Anti-fibrotic research in cardiac, renal, or pulmonary models where independently replicated mechanisms matter.
Evidence Context Favoring BPC-157
Broader tissue repair or GI protection research, accepting that independent replication is lacking.
Side-by-Side Snapshot
| Evidence grade | Ac-SDKP: Level D BPC-157: Level B |
|---|---|
| Research status | Ac-SDKP: Preclinical BPC-157: Phase 2 |
| Primary category | Ac-SDKP: Healing & Recovery BPC-157: Healing & Recovery |
| Cited studies | Ac-SDKP: 3 BPC-157: 10 |